Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
37
RMTI Quote, Financials, Valuation and Earnings
Last price:
$2.07
Seasonality move
:
14.82%
Day range:
$1.98 - $2.12
52-week range:
$1.16 - $5.15
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.64x
P/B ratio:
2.31x
Volume:
479.7K
Avg. volume:
1.1M
1-year change:
16.2%
Market cap:
$67.2M
Revenue:
$83.6M
EPS (TTM):
-$0.06
Analysts' Opinion
-
Consensus RatingRockwell Medical has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Rockwell Medical has an estimated upside of 212.5% from its current price of $2.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.08.
Fair Value
-
According to the consensus of 0 analysts, Rockwell Medical has 212.5% upside to fair value with a price target of -- per share.
RMTI vs. S&P 500
-
Over the past 5 trading days, Rockwell Medical has overperformed the S&P 500 by 4.03% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Rockwell Medical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rockwell Medical has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Rockwell Medical reported revenues of $28.3M.
Earnings Growth
-
Rockwell Medical has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Rockwell Medical reported earnings per share of $0.04.
Enterprise value:
57.8M
EV / Invested capital:
1.52x
Price / LTM sales:
0.64x
EV / EBIT:
69.06x
EV / Revenue:
0.58x
PEG ratio (5yr expected):
--
EV / Free cash flow:
21.94x
Price / Operating cash flow:
24.17x
Enterprise value / EBITDA:
19.11x
Gross Profit (TTM):
$16.7M
Return On Assets:
-2.33%
Net Income Margin (TTM):
-1.25%
Return On Equity:
-5.32%
Return On Invested Capital:
-3.86%
Operating Margin:
6.84%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $68.8M | $80.8M | $98.9M | $23.8M | $28.3M | |
| Gross Profit | -$495K | $8.2M | $16.7M | $2.2M | $6.2M | |
| Operating Income | -$23.2M | -$8.1M | $580K | -$1.7M | $1.9M | |
| EBITDA | -$22.1M | -$6.6M | $3M | -$897K | $2.5M | |
| Diluted EPS | -$2.54 | -$0.55 | -$0.06 | -$0.07 | $0.04 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $77.9M | $46.1M | $42.4M | $28.2M | $34.2M | |
| Total Assets | $85.2M | $58.7M | $54.2M | $52.6M | $57.1M | |
| Current Liabilities | $12.7M | $21.8M | $19.3M | $21.4M | $14.2M | |
| Total Liabilities | $43.2M | $47.6M | $38.1M | $31.1M | $27.9M | |
| Total Equity | $42.1M | $11.1M | $16.1M | $21.5M | $29.1M | |
| Total Debt | $20.9M | $22.5M | $15.1M | $9.5M | $8.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$25.8M | -$9.5M | $3.3M | -$3.8M | $4.3M | |
| Cash From Investing | -$5.1M | -$1.8M | -$2.5M | -$10.3M | -$6.1M | |
| Cash From Financing | $20.5M | $6.1M | $3.8M | $12.8M | $2.3M | |
| Free Cash Flow | -$26.2M | -$9.8M | $2.6M | -$3.8M | $4.1M | |
RMTI
Sector
Market Cap
$67.2M
$44.6M
Price % of 52-Week High
40.39%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
-5.64%
-0.68%
1-Year Price Total Return
16.2%
-29.09%
Beta (5-Year)
1.379
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.08
200-day SMA
Sell
Level
$2.38
Bollinger Bands (100)
Sell
Level
2.27 - 3.81
Chaikin Money Flow
Sell
Level
-191.2M
20-day SMA
Sell
Level
$2.16
Relative Strength Index (RSI14)
Sell
Level
37.57
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-72.2222
50-day SMA
Sell
Level
$2.92
MACD (12, 26)
Sell
Level
-0.23
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
113.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.0952)
Sell
CA Score
(Annual)
Level (-1.0108)
Sell
Beneish M-Score
(Annual)
Level (-0.7516)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.592)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
Stock Forecast FAQ
In the current month, RMTI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RMTI average analyst price target in the past 3 months is --.
-
Where Will Rockwell Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rockwell Medical share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Rockwell Medical?
Analysts are divided on their view about Rockwell Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rockwell Medical is a Sell and believe this share price will drop from its current level to --.
-
What Is Rockwell Medical's Price Target?
The price target for Rockwell Medical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RMTI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rockwell Medical is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RMTI?
You can purchase shares of Rockwell Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rockwell Medical shares.
-
What Is The Rockwell Medical Share Price Today?
Rockwell Medical was last trading at $2.07 per share. This represents the most recent stock quote for Rockwell Medical. Yesterday, Rockwell Medical closed at $2.08 per share.
-
How To Buy Rockwell Medical Stock Online?
In order to purchase Rockwell Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
